Diploma (LON:DPLM) Reaches New 52-Week High Following Insider Buying Activity

Diploma PLC (LON:DPLM) hit a new 52-week high during mid-day trading on Monday following insider buying activity. The stock traded as high as GBX 7,360 and last traded at GBX 7,355, with a volume of 4569454 shares changing hands. The stock had previously closed at GBX 7,240.

Specifically, insider Katie Bickerstaffe  acquired 47 shares of Diploma stock in a transaction on Thursday, July 16th. The shares were acquired at an average price of GBX 7,050 per share, with a total value of £3,313.50. Also, insider Wilson Ng acquired 424 shares of the firm’s stock in a transaction dated Thursday, July 16th. The shares were purchased at an average cost of GBX 7,066 per share, for a total transaction of £29,959.84. In other news, insider Katie Bickerstaffe  bought 133 shares of the stock in a transaction dated Thursday, July 16th. The stock was purchased at an average cost of GBX 7,048 per share, for a total transaction of £9,373.84.

Analyst Upgrades and Downgrades

DPLM has been the topic of several research reports. JPMorgan Chase & Co. boosted their price target on shares of Diploma from GBX 5,120 to GBX 5,760 and gave the stock a “neutral” rating in a research report on Friday, March 27th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Diploma from GBX 6,400 to GBX 7,200 and gave the company a “buy” rating in a research report on Wednesday, May 20th. Royal Bank Of Canada lifted their price objective on shares of Diploma from GBX 7,300 to GBX 7,400 and gave the stock an “outperform” rating in a research note on Friday. Berenberg Bank restated a “buy” rating and set a GBX 9,000 target price on shares of Diploma in a research report on Monday. Finally, Jefferies Financial Group restated a “hold” rating and set a GBX 7,000 target price on shares of Diploma in a research report on Friday, May 29th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of GBX 7,044.29.

Diploma News Roundup

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Berenberg Bank reiterated its buy rating on Diploma PLC and lifted its price target to GBX 9,000, reinforcing a positive analyst view on the stock’s valuation and growth prospects. Broker views source
• Positive Sentiment: Several senior insiders bought shares, including Mandy Gradden (1,000 shares), Wilson Ng (424 shares), and Katie Bickerstaffe (multiple purchases), which investors often view as a sign management believes the stock is undervalued. TipRanks article
• Neutral Sentiment: An article highlighting Diploma as a potential long-term compounding stock added visibility, but it did not include new company-specific financial results or guidance. Yahoo Finance article

Diploma Price Performance

The company has a quick ratio of 0.80, a current ratio of 2.06 and a debt-to-equity ratio of 47.65. The company has a market capitalization of £9.88 billion, a PE ratio of 52.34, a price-to-earnings-growth ratio of 2.82 and a beta of 0.92. The firm’s 50 day simple moving average is GBX 6,979.65 and its 200 day simple moving average is GBX 6,257.69.

Diploma (LON:DPLM) last announced its earnings results on Tuesday, May 19th. The company reported GBX 74.70 earnings per share for the quarter. The business had revenue of £851.10 million for the quarter. Diploma had a net margin of 9.42% and a return on equity of 18.55%. As a group, research analysts anticipate that Diploma PLC will post 163.7995512 EPS for the current fiscal year.

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.